Anti-CD20 Antibody + Chemo Benefits CLL With Comorbidity Doctors Lounge For patients with previously untreated chronic lymphocytic leukemia and coexisting conditions, combining an anti-CD20 antibody (rituximab or obinutuzumab) with chemotherapy is associated with improved outcomes, according to a study published online ... |
